Attached files
| file | filename |
|---|---|
| EX-99.6 - EXHIBIT 99.6 - ALBANY MOLECULAR RESEARCH INC | v440429_ex99-6.htm |
| EX-99.5 - EXHIBIT 99.5 - ALBANY MOLECULAR RESEARCH INC | v440429_ex99-5.htm |
| EX-99.3 - EXHIBIT 99.3 - ALBANY MOLECULAR RESEARCH INC | v440429_ex99-3.htm |
| EX-99.2 - EXHIBIT 99.2 - ALBANY MOLECULAR RESEARCH INC | v440429_ex99-2.htm |
| EX-99.1 - EXHIBIT 99.1 - ALBANY MOLECULAR RESEARCH INC | v440429_ex99-1.htm |
| 8-K - FORM 8-K - ALBANY MOLECULAR RESEARCH INC | v440429_8k.htm |
Exhibit 99.4
Balance sheet 31.12.2014
| (in thousands of Euro) | 31
December 2014 Consolidated Lauro 57 IFRS | Deconsolidation Lauro 57 | 31
December 2014 Consolidated Euticals IFRS | ADJ R&D | 31
December 2014 Consolidated Euticals IFRS ADJ | |||||||||||||||
| Intangible assets | 117,839 | (91,841 | ) | 25,998 | (8,977 | ) | 17,021 | |||||||||||||
| Tangible assets | 77,152 | 0 | 77,152 | 77,152 | ||||||||||||||||
| Deferred tax assets | 11,043 | (1 | ) | 11,042 | 2,810 | 13,853 | ||||||||||||||
| Other non-current assets | 1,816 | 0 | 1,816 | 1,816 | ||||||||||||||||
| Total non-current assets | 207,850 | (91,841 | ) | 116,009 | (6,167 | ) | 109,842 | |||||||||||||
| Inventories | 64,292 | (1 | ) | 64,291 | 64,291 | |||||||||||||||
| Trade receivables | 42,241 | 0 | 42,241 | 42,241 | ||||||||||||||||
| Current tax receivables | 1,039 | (100 | ) | 939 | 939 | |||||||||||||||
| Other current assets | 3,569 | (193 | ) | 3,376 | 3,376 | |||||||||||||||
| Cash and cash equivalents | 13,396 | (46 | ) | 13,350 | 13,350 | |||||||||||||||
| Total current assets | 124,537 | (339 | ) | 124,198 | - | 124,198 | ||||||||||||||
| Asset of disposal group classified as held for sale | 5,000 | - | 5,000 | 5,000 | ||||||||||||||||
| Total assets | 337,387 | (92,180 | ) | 245,207 | (6,167 | ) | 239,041 | |||||||||||||
| Share capital | 50,000 | (15,629 | ) | 34,371 | 34,371 | |||||||||||||||
| Share premium reserve | 167,500 | (143,109 | ) | 24,391 | 24,391 | |||||||||||||||
| Other reserves | (11,470 | ) | 38,058 | 26,588 | 26,588 | |||||||||||||||
| Profit (loss) carried forward | (28,856 | ) | (3,967 | ) | (32,823 | ) | (5,042 | ) | (37,865 | ) | ||||||||||
| Profit (loss) for the period | (4,224 | ) | (541 | ) | (4,765 | ) | (1,125 | ) | (5,890 | ) | ||||||||||
| Net equity | 172,950 | (125,188 | ) | 47,762 | (6,167 | ) | 41,595 | |||||||||||||
| Non-current financial liabilities | 1,433 | (0 | ) | 1,433 | 1,433 | |||||||||||||||
| Liabilities for employees’ benefits | 11,222 | 0 | 11,222 | 11,222 | ||||||||||||||||
| Non-current provisions for risks and charges | 7,463 | 1 | 7,464 | 7,464 | ||||||||||||||||
| Other non-current liabilities | - | - | - | - | ||||||||||||||||
| Deferred tax liabilities | 163 | - | 163 | 163 | ||||||||||||||||
| Total non-current liabilities | 20,281 | 1 | 20,282 | - | 20,282 | |||||||||||||||
| Current financial liabilities | 94,077 | 32,888 | 126,965 | 126,965 | ||||||||||||||||
| Trade payables | 30,039 | (119 | ) | 29,920 | 29,920 | |||||||||||||||
| Tax payables | 2,668 | (8 | ) | 2,660 | 2,660 | |||||||||||||||
| Current provisions for risks and charges | 1,353 | (1 | ) | 1,352 | 1,352 | |||||||||||||||
| Other current payables | 15,348 | 247 | 15,595 | 15,595 | ||||||||||||||||
| Total current liabilities | 143,485 | 33,007 | 176,492 | - | 176,492 | |||||||||||||||
| Total liabilities | 163,766 | 33,008 | 196,774 | - | 196,774 | |||||||||||||||
| Liabilities of disposal group classified as held for sale | 671 | - | 671 | 671 | ||||||||||||||||
| Total equity and liabilities | 337,387 | (92,180 | ) | 245,207 | (6,167 | ) | 239,041 | |||||||||||||
Profit & Loss 31.12.2014
| (in thousands of Euro) | 31
December 2014 Consolidated Lauro 57 IFRS | Deconsolidation Lauro 57 | 31
December 2014 Consolidated Euticals IFRS | ADJ R&D | 31
December 2014 Consolidated Euticals IFRS ADJ | |||||||||||||||
| Revenues | 186,113 | - | 186,113 | 186,113 | ||||||||||||||||
| Other revenue and income | 2,761 | (214 | ) | 2,547 | 2,547 | |||||||||||||||
| Total Revenues and incomes | 188,874 | (214 | ) | 188,660 | 188,660 | |||||||||||||||
| Raw, ancillary and consumable materials and goods | (69,695 | ) | - | (69,695 | ) | (69,695 | ) | |||||||||||||
| Service costs and costs of third-party assets | (43,217 | ) | 385 | (42,832 | ) | (42,832 | ) | |||||||||||||
| Employee expenses | (53,648 | ) | - | (53,648 | ) | (53,648 | ) | |||||||||||||
| Other operating expenses | (3,075 | ) | (111 | ) | (3,186 | ) | (3,186 | ) | ||||||||||||
| Change in inventories | (3,243 | ) | - | (3,243 | ) | (3,243 | ) | |||||||||||||
| Capitalization of internal costs | 5,631 | - | 5,631 | (4,957 | ) | 674 | ||||||||||||||
| Depreciation, Amortization and Asset value adjustments | (21,508 | ) | - | (21,508 | ) | 3,313 | (18,195 | ) | ||||||||||||
| Total operating costs | (188,755 | ) | 274 | (188,481 | ) | (1,644 | ) | (190,125 | ) | |||||||||||
| Operating profit | 119 | 60 | 179 | (1,644 | ) | (1,465 | ) | |||||||||||||
| EBITDA | 21,627 | 60 | 21,687 | (4,957 | ) | 16,730 | ||||||||||||||
| Financial income | 11 | - | 11 | 11 | ||||||||||||||||
| Financial expenses | (6,243 | ) | (601 | ) | (6,844 | ) | (6,844 | ) | ||||||||||||
| Profit (loss) before taxes | (6,113 | ) | (541 | ) | (6,654 | ) | (1,644 | ) | (8,298 | ) | ||||||||||
| Income taxes | 1,889 | - | 1,889 | 519 | 2,408 | |||||||||||||||
| Net profit (loss) from operations | (4,224 | ) | (541 | ) | (4,765 | ) | (1,125 | ) | (5,890 | ) | ||||||||||